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REVIEW CURRENTOPINION Nuclear imaging in the diagnosis of primary
aldosteronism Copyright 
www.co-endocrinology.coma a bAndrew S. Powlson , Mark Gurnell , and Morris J. BrownPurpose of review
Primary aldosteronism is increasingly recognized as a common secondary cause of hypertension.
Successful demonstration of a unilateral cause (e.g. a classical ‘Conn’s adenoma’) offers the potential for
curative adrenalectomy. Adrenal vein sampling (AVS), in conjunction with cross-sectional imaging, remains
the ‘gold standard’ for distinguishing unilateral and bilateral disease, but is technically demanding and
frequently unsuccessful or inconclusive. As such, alternative strategies for lateralization, including nuclear
medicine techniques, are being developed and brought into clinical practice.
Recent findings
Metomidate, a potent ligand of CYP11B1 and CYP11B2, can be C11H3-labelled as a PET tracer and has
been shown to offer a rapid noninvasive alternative to AVS for localizing unilateral aldosterone-producing
adenomas.
Summary
Increasing experience with 11C-metomidate PET-CT supports its use as an adjunct to AVS when this has
failed, is ambiguous, or cannot be undertaken.
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Hypertension is a major determinant of excess
cardiovascular morbidity and mortality, especially
myocardial infarction, and stroke. Well estab-
lished algorithms for stepwise pharmacological
management of ‘essential’ hypertension exist,
alongside lifestyle interventions [1
&
]. However,
identifying a specific cause for hypertension, such
as primary (hyper)aldosteronism, yields the
possibility of targeted drug therapy or, more entic-
ingly, the potential for surgical cure. Indeed, the
impetus to diagnose and manage primary aldos-
teronism is further strengthened by the recog-
nition that aldosterone excess is associated with
morbidity over and above that in a matched popu-
lation with primary hypertension [2]. Primary
aldosteronism is increasingly recognized as a com-
mon secondary cause of hypertension and is
reported in approximately 5–10% of all hyperten-
sive patients and in 20–25% of those with docu-
mented treatment-resistant hypertension [3,4]. In
around half of all cases of primary aldosteronism,
the hypersecretion is attributable to a single
aldosterone-producing adenoma (APA) in one
adrenal gland, and when this is the case© 2015 Wolters Kluwer adrenalectomy offers the possibility of a cure of
hypertension in a significant proportion of
patients. However, currently only one in 10
eligible patients proceed to surgery [3]. Perhaps
the most significant hurdle is the need to confirm
that primary aldosteronism is indeed the result of
unilateral disease, thus distinguishing an isolated
APA from other causes of primary aldosteronism,
including bilateral idiopathic hyperaldosteronismHealth, Inc. All rights reserved.
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KEY POINTS
 Unilateral primary aldosteronism is a common cause of
hypertension and is potentially curable by
adrenalectomy.
 Diagnosis of unilateral primary aldosteronism has
conventionally relied on AVS, which is invasive and is
often uninformative as a result of inherent technical
challenges.
 11C-metomidate PET-CT offers a rapid noninvasive
alternative to AVS for localizing unilateral APAs.
Nuclear imaging in primary aldosteronism Powlson et al.and familial syndromes, which may coexist with a
nonfunctioning adrenal adenoma (incidentaloma)
[5]. Currently, nonlateralizing primary aldosteron-
ism is treated medically, but this has been shown
to have poorer cardiovascular outcomes than
surgery for unilateral disease [6,7].ADRENAL VEIN SAMPLING IN THE
DIAGNOSIS OF PRIMARY
ALDOSTERONISM
The first step in establishing lateralization typi-
cally involves cross-sectional imaging [thin-slice
computed tomography (CT) or MRI]. In patients
under 35 years of age, the finding of a classical
solitary Conn’s adenoma (1–2 cm diameter), with
an entirely normal contralateral gland may be
sufficient to proceed direct to surgery [8]. In the
majority of cases however, further proof of unilat-
erality is required, as several studies have shown
that reliance on cross-sectional imaging alone is
fraught with risk. This is nonspecific, as nonfunc-
tioning adrenal incidentalomas are common in
patients more than 40 years of age (4–7% of the
population) [5]. It is also insensitive as small nod-
ules (<1 cm in diameter) may be missed, especially
if located within the body of the adrenal, and a
common sub-tier of small APAs was recently ident-
ified through finding hallmark somatic mutations,
distinct from those in classical Conn’s adenomas
[9
&
]. The gold-standard lateralization procedure
remains bilateral adrenal vein sampling (AVS)
[10]. However, this is technically challenging
and in many centres the right adrenal vein is
successfully cannulated in only 50–80% of cases
[11,12]. In addition, several different sets of
criteria exist for defining both successful adrenal
vein cannulation and subsequently lateralization,
based on the measurement of plasma cortisol and
aldosterone levels in both adrenal veins and in
the inferior vena cava [13]. In recognition, that
both cortisol and aldosterone secretion can be Copyright © 2015 Wolters Kluwe
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tropin stimulation and/or sampling of the adrenal
veins simultaneously, rather than sequentially.
Both measures aim to reduce the risk of false
lateralization [14,15
&
].
The difficulties inherent in achieving successful
AVS, coupled with the potential need for many
more patients to be referred for lateralizing studies
as primary aldosteronism is increasingly recognized,
has led to a search for alternative strategies to cir-
cumvent the ‘hurdle’ of AVS in progressing patients
to surgery. Ku¨pers et al. [16] assessed the potential
utility of a clinical scoring system in predicting
unilateral disease. In 87 patients with primary aldos-
teronism and successful AVS, lateralization was
demonstrated in 49 patients. All 26 patients with
a typical Conn’s adenoma and serum potassium
level less than 3.5mmol/l or estimated glomerular
filtration rate at least 100ml/min/1.73m2 (or both)
had unilateral primary aldosteronism; this rule had
100% specificity and 53% sensitivity. However, sub-
sequent studies from both the UK [17
&
] and
Germany (German Conn’s Registry) [18
&
] were
unable to reproduce the 100% specificity (88.5 and
80%, respectively). Accordingly, interest has been
rekindled in functional imaging techniques to comp-
lement cross-section imaging and AVS and which
would allow a more definitive assessment of lateral-
ization to be delivered tomanymore patients than is
currently achievable in the majority of centres.NUCLEAR MEDICINE IMAGING IN THE
DIAGNOSIS OF PRIMARY
ALDOSTERONISM
Norcholesterol scintigraphy
Historically, 131I-iodomethyl-norcholesterol (NP-
59) and 75Se-selenomethyl-19-norcholesterol have
been used as scintigraphic tracers for the detection
of APAs [19,20]. In both cases, high dose dexa-
methasone treatment (e.g. 8mg per day for >1
week) to suppress tracer uptake by nonautonomous
adrenal cortex is given, and patients are required to
attend for image capture on several occasions. In
addition, the accuracy of distinguishing an APA
from bilateral hyperplasia is as low as 47% in stud-
ies using planar imaging, which in particular lacks
the resolution to reliably detect lesions less than
1.5–2 cm in diameter. It may also erroneously
identify gastrointestinal activity as adrenal uptake.
Single photon emission computed tomography/CT
has been proposed as a means of addressing these
concerns, although significant numbers of false-
positive and false-negative categorizations have
been observed even in modern case series [21].r Health, Inc. All rights reserved.
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Adrenal cortex and medullaAlthough attempts have been made to improve
sensitivity and specificity with semiquantitative
approaches to this technique [22
&
], the require-
ment for prolonged dexamethasone suppression,
sequential imaging, and limited tracer availability
mean that it is unlikely to be considered a viable
alternative to AVS in most centres.11C-metomidate PET-CT
Recent interest has focussed on the potential
utility of PET-CT, with its increased spatial resol-
ution, as an alternative imaging modality for the
detection of functional autonomy in primary
aldosteronism. Metomidate is a potent inhibitor
of CYP11B1 (11b-hydroxylase) and CYP11B2
(aldosterone synthase). It is the methyl analogue
of etomidate, an ethyl-imidazole anaesthetic agent
which is used clinically in subhypnotic doses as an
inhibitor of adrenal steroidogenesis in the man-
agement of refractory Cushing’s syndrome [23].
Metomidate (itself used as a veterinary anaesthetic
until the 1970s) can be C11H3-labelled as a PET
radiotracer (11C-metomidate), and proof of con-
cept of its high affinity binding to adrenal cortex
was established in vitro and in primate studies as
far back as 1998 [24]. In the first human appli-
cation [25], 15 patients underwent 11C-methion-
ine PET-CT prior to surgery for a unilateral adrenal
mass. The nine histologically diagnosed adreno-
cortical tumours each demonstrated high uptake
and could be reliably discriminated from the six
lesions that were not of cortical origin. In a larger
follow-up series, comprising 73 patients who under-
went surgery for suspected adrenal lesions, the six
histologically confirmed APAs demonstrated the
highest 11C-metomidate uptake, with a standardized
uptake value (SUV) of 30.7 compared with 18.4 in
nonfunctional adenomas [26]. These findings
suggested that 11C-metomidate PET-CT might offer
an alternative technique for the lateralization of
Conn’s adenomas and provided preliminary evi-
dence to support a formal study of sensitivity and
specificity in an unselected cohort of patients with
unilateral and bilateral primary aldosteronism.
We recently reported the findings of such a
study in which the potential utility of 11C-meto-
midate PET-CT for establishing lateralization in
primary aldosteronism was assessed through direct
comparison with the current ‘gold standard’ of
AVS in a prospective noninferiority trial [27
&&
].
Based on the findings of a small pilot study, all
patients received a short course of low-dose dexa-
methasone (0.5mg 6-hourly for 72h) immediately
prior to undergoing a single PET-CT scan. This well
tolerated pretreatment regimen improved the Copyright © 2015 Wolters Kluwer 
152 www.co-endocrinology.comsignal to background ratio through suppression
of 11C-metomidate uptake by nonadenomatous
adrenal cortex. Interestingly, pretreatment with
fludrocortisone (400mg daily), either alone or in
combination with the dexamethasone, showed no
additional benefit. Of 44 recruited individuals, 39
had primary aldosteronism and five a nonfunc-
tioning adrenal incidentaloma (these individuals
were normotensive and had no clinical or bio-
chemical evidence of adrenal hyperfunction). In
the group with primary aldosteronism, 19 had a
unilateral cause identified at AVS, and a further six
were confirmed to have unilateral disease on the
basis that subsequent unilateral adrenalectomy
reversed their biochemical primary aldosteronism
and cured their hypertension, despite a failure to
conclusively lateralize on AVS (the decision to
recommend surgery in these cases was taken inde-
pendently by the referring physician with primary
responsibility for the patient’s care). Of those
deemed to have unilateral primary aldosteronism
on AVS, all but three proceeded to surgery.
All operated cases demonstrated a histological
adenoma with dominant CYP11B2 expression,
and aldosterone production in primary culture
of cells from the resected nodule, which exceeded
that of adjacent normal tissue. Ten patients met
the criteria for a diagnosis of bilateral primary
aldosteronism. Four patients were excluded from
the final analysis as they did not proceed to
surgery, in the absence of a clear-cut AVS result
and indication for surgery.
11C-metomidate uptake was calculated as the
SUVmax during the final 10min of data acquisition.
In patients with primary aldosteronism and a unilat-
eral APA, the mean SUVmax over the adenoma
[21.71.6 (range 10.3–38.9)] was significantly
greater than in the surroundingnormal adrenal tissue
SUVmax [13.80.6 (P<0.00003)] [27&&]. Patients
with an adrenal incidentaloma (and no clinical
or biochemical evidence of primary aldostero-
nism) demonstrated a lower mean tumour
SUVmax of 11.53.3 (range 0–16.6). Patients with
primary aldosteronism and bilateral adrenal hyper-
plasia or bilateral adenomas had a mean SUVmax of
17.31.2 [27&&]. Calculation of the ratio of tumour
SUVmax to normal background adrenal SUVmax
revealed that an SUV ratio greater than 1.25 afforded
optimal sensitivity (76%) and specificity (87%).
Importantly, specificity increased to100%inpatients
with an SUVmax ratio greater than 1.25 and absolute
tumour SUVmax of greater than 17 [27
&&
].
Taken together, these findings provide confir-
matory evidence that 11C-metomidate PET-CT offers
a noninferior alternative to AVS in the diagnosis of
unilateral primary aldosteronism. Since our originalHealth, Inc. All rights reserved.
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(a) (b)
FIGURE 2. Case 2 – 11C-metomidate PET-CT identifies unilateral primary aldosteronism despite mineralocorticoid receptor
antagonist therapy. A 63-year-old man with a 10-year history of primary aldosteronism treated medically with
mineralocorticoid receptor antagonist therapy was referred for reassessment and consideration of possible adrenalectomy. His
blood pressure had previously proved difficult to control until the introduction of spironolactone, and the patient was reluctant
to discontinue this to permit adrenal vein sampling (AVS). MRI demonstrated an 11mm right adrenal nodule (a). 11C-
metomidate PET-CT confirmed avid tracer uptake within this lesion [target:background standardized uptake value (SUV)max
ratio 2.45] (b). He underwent laparoscopic right adrenalectomy, with histology confirming an adrenal cortical adenoma.
Postoperatively, he had complete resolution of his biochemical hyperaldosteronism and hypertension with no requirement for
antihypertensive therapy. This case illustrates the utility of 11C-metomidate PET-CT in establishing unilateral primary
aldosteronism even in patients who are unable or unwilling to discontinue mineralocorticoid receptor antagonist therapy.
(a) (b)
FIGURE 1. Case 1 – 11C-metomidate PET-CT identifies unilateral primary aldosteronism in a patient with equivocal cross-
sectional imaging. A 56-year-old man with significant ischaemic coronary disease had poorly controlled hypertension despite
treatment with multiple agents. Further investigation confirmed a diagnosis of primary aldosteronism. CT revealed an 8mm
lipid poor right adrenal nodule, which could not be fully characterized because of its small size (a). In addition, the body of
the left adrenal gland was noted to be bulky, but without a discrete lesion. Adrenal vein sampling (AVS) demonstrated a right-
sided gradient (>4:1), but in light of the equivocal cross-sectional imaging findings the patient proceeded to 11C-metomidate
PET-CT. This confirmed increased tracer uptake [target:background standardized uptake value (SUV)max ratio 1.44] in the right
adrenal nodule only (b). The patient underwent laparoscopic right adrenalectomy, which confirmed a classical small Conn’s
adenoma. Postoperatively, he had complete resolution of his hyperaldosteronism and required just single agent therapy
(amlodipine) to achieve satisfactory blood pressure control. This case illustrates how the increased spatial resolution of
11C-metomidate PET-CT facilitates the reliable identification of subcentimetre Conn’s adenomas.
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FIGURE 3. Case 3 – 11C-metomidate PET-CT in bilateral primary aldosteronism with adrenal incidentalomas. A 52-year-old
man was found to have primary aldosteronism during participation in a study of treatment-resistant hypertension. CT showed
7mm right and 16 mm left adenomas (a and b), but with no lateralization on AVS. On 11C-metomidate PET-CT, both
adenomas were seen to be relatively cold, compared with adjacent adrenal (c and d), which was not, therefore, suggestive of
a surgically-remediable unilateral cause. His blood pressure was subsequently controlled on conventional triple therapy
(losartan, amlodipine, and bendroflumethiazide) with the addition of the mineralocorticoid receptor antagonist eplerenone,
and amiloride. This case demonstrates how 11C-metomidate PET-CT may be used in the confirmation of bilateral disease, and
the distinction between aldosterone-producing adenomas (APAs) and nonfunctional incidentalomas.
Adrenal cortex and medullastudy, we have confirmed and extended our find-
ings in a much larger cohort of patients (illustrative
cases, Figs. 1–4), with confirmation that PET-CT
confers significant benefits particularly with respect
to the identification of small APAs (where the
enhanced spatial resolution compared with conven-
tional scintigraphy is required), and in patients in
whom AVS is technically challenging, inconclusive
or not feasible.
The downside of 11C-metomidate PET-CT is the
20-min half-life of 11C-isotopes, mandating an on-
site cyclotron. Two patients can be studied for each
synthesis, making the costs comparable to, or lower
than, those for AVS, and a number of centres in the
UK and Scandinavia are now establishing and eval-
uating 11C-metomidate PET-CT. Elsewhere, there is
interest in radiolabels with longer half-lives, with
123I-metomidate or 131I-metomidate being used Copyright © 2015 Wolters Kluwer 
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adrenocortical carcinomas [28
&&
]. However, the
different analogues may vary in relative affinity
for the aldosterone-producing and cortisol-produc-
ing enzymes (CYP11B2 and CYP11B1), with critical
difference therefore in their ability to distinguish
APAs fromadjacent adrenal tissue [29]. Theymayalso
lack the spatial resolution afforded by PET-CT.CONCLUSION
Primary aldosteronism is a common cause of hyper-
tension and in unilateral disease, which accounts for
approximately 50% of cases, is potentially curable
surgically. Lateralization with AVS is technically
demanding and invasive and in many centres is
frequently unsuccessful. 11C-metomidate PET-CT
offers a rapid noninvasive alternative to AVS forHealth, Inc. All rights reserved.
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(a) (b) (c)
FIGURE 4. Case 4 – 11C-metomidate PET-CT in bilateral primary aldosteronism with ‘hot’ aldosterone-producing adenomas
(APAs). A 48-year-old woman with 10-year history of severe hypertension and primary aldosteronism had bilateral adrenal
adenomas (a and b). AVS did not lateralize. 11C-metomidate PET-CT shows bilaterally hot adenomas, with higher
standardized uptake values (SUV)max than adjacent adrenals (c). Her blood pressure was subsequently well controlled by
spironolactone and amlodipine.
Nuclear imaging in primary aldosteronism Powlson et al.localizing unilateral APAs. Our increasing experience
suggests it may have particular utility in certain set-
tings, such as when mineralocorticoid receptor
antagonists cannot be easily or safely withdrawn,
or with subcentimetre lesions and equivocal cross-
sectional imaging. Furthermore, in our experience
patients universally prefer this noninvasive option.
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